ANTX
AN2 TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
ANTX Profile
An2 Therapeutics, Inc.
A biopharmaceutical company focused on developing treatments for infectious diseases and cancer
1800 El Camino Real, Suite D, Menlo Park, California 94027
--
AN2 Therapeutics, Inc., was incorporated in Delaware in February 2017. The company is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with unmet needs. The Company's initial drug candidate is epetraborole, which the Company is investigating as a potential once-daily oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacteria (" NTM ") pulmonary disease, a rare, chronic and progressive infectious disease caused by bacteria called mycobacteria that can cause irreversible lung damage and can be fatal.
